Plain Language Summaries move published research beyond the basic definition of Open Access – availability – toward a more ambitious goal of understandability.
Interviews with Dr. Oleksandr Gorbenko, Adeline Rosenberg, & Joanne Walker
Subscribe: Apple Podcasts | Stitcher | Email | Download
Last week, at the European Meeting of the International Society of Medical Publication Professionals, pharmaceutical firm Ipsen announced a breakthrough dramatically affecting doctors and patients alike.
This important research advancement did not occur in any laboratory – it emerged after close examination of the drug company’s communications policy.
In the lab, Ipsen concentrates its research in three key therapeutic areas: oncology, rare disease and neuroscience. At the writing desk, it is also a leader in making that research widely available. Since 2019, Ipsen has committed to publishing its research exclusively with Open Access journals.
Now, Ipsen has become the first pharmaceutical company to commit to publishing, as a minimum, a 250-word plain language summary alongside all company-sponsored journal publications that include data from human studies. This commitment will apply to articles published from July 2022.
We devote this program to the Ipsen announcement and what it means for patients, publishers and physicians. Featured guests are Dr. Oleksandr Gorbenko, Ipsen global patient-centricity director; Adeline Rosenberg, medical writer, Oxford PharmaGenesis; and Joanne Walker, head of publishing solutions, the Future Science Group.
